CN114805019B - Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology - Google Patents
Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology Download PDFInfo
- Publication number
- CN114805019B CN114805019B CN202210438652.8A CN202210438652A CN114805019B CN 114805019 B CN114805019 B CN 114805019B CN 202210438652 A CN202210438652 A CN 202210438652A CN 114805019 B CN114805019 B CN 114805019B
- Authority
- CN
- China
- Prior art keywords
- continuous flow
- reaction
- flow reaction
- aryl
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 34
- 230000002194 synthesizing effect Effects 0.000 title claims description 7
- 238000005516 engineering process Methods 0.000 title abstract description 13
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 22
- ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 claims abstract description 13
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohexene oxide Natural products O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims abstract description 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims abstract description 10
- 238000007142 ring opening reaction Methods 0.000 claims abstract description 9
- 238000005086 pumping Methods 0.000 claims abstract 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000002474 experimental method Methods 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000012074 organic phase Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 150000007517 lewis acids Chemical group 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000004809 Teflon Substances 0.000 claims description 2
- 229920006362 Teflon® Polymers 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 125000001979 organolithium group Chemical group 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 238000012805 post-processing Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 238000010924 continuous production Methods 0.000 claims 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 238000005265 energy consumption Methods 0.000 abstract description 5
- 230000003321 amplification Effects 0.000 abstract description 4
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 4
- 238000005112 continuous flow technique Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 16
- 229910015900 BF3 Inorganic materials 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- -1 amino, hydroxyl Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- QBELEDRHMPMKHP-UHFFFAOYSA-N 1-bromo-2-chlorobenzene Chemical compound ClC1=CC=CC=C1Br QBELEDRHMPMKHP-UHFFFAOYSA-N 0.000 description 2
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 2
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- LJKHFBFVVANKMT-UHFFFAOYSA-N O=C1C(C2=CC=CC=C2C)(N(=O)=O)CCCC1 Chemical compound O=C1C(C2=CC=CC=C2C)(N(=O)=O)CCCC1 LJKHFBFVVANKMT-UHFFFAOYSA-N 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QDFKKJYEIFBEFC-UHFFFAOYSA-N 1-bromo-3-fluorobenzene Chemical compound FC1=CC=CC(Br)=C1 QDFKKJYEIFBEFC-UHFFFAOYSA-N 0.000 description 1
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
- DTTDXHDYTWQDCS-UHFFFAOYSA-N 1-phenylcyclohexan-1-ol Chemical compound C=1C=CC=CC=1C1(O)CCCCC1 DTTDXHDYTWQDCS-UHFFFAOYSA-N 0.000 description 1
- YXADWCNDSYNYQT-UHFFFAOYSA-N 2-(2-chlorophenyl)cyclohexan-1-ol Chemical compound OC1CCCCC1C1=CC=CC=C1Cl YXADWCNDSYNYQT-UHFFFAOYSA-N 0.000 description 1
- FTDCRHPZMQFMID-UHFFFAOYSA-N 2-(2-methylphenyl)cyclohexan-1-ol Chemical compound CC1=CC=CC=C1C1C(O)CCCC1 FTDCRHPZMQFMID-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
- C07C29/10—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes
- C07C29/103—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers
- C07C29/106—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers of oxiranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/08—Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/02—Lithium compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00002—Chemical plants
- B01J2219/00004—Scale aspects
- B01J2219/00006—Large-scale industrial plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域Technical field
本发明属于化学合成技术领域,尤其涉及一种基于连续流反应技术制备2-芳基-1-环己醇的方法。The invention belongs to the field of chemical synthesis technology, and in particular relates to a method for preparing 2-aryl-1-cyclohexanol based on continuous flow reaction technology.
背景技术Background technique
2-芳基-1-环己醇是合成众多生物活性分子、药物、及其他材料等的重要中间体。例如:4-环烷氧基苯腈是一种雄激素受体调节剂。可以有效减少皮脂分泌和刺激头发生长,从而给脱发患者带来了福音;氯胺酮是一类静脉全身麻醉药,临床上用于全身麻醉剂或麻醉诱导剂,并有支气管扩张的作用,故也适用于哮喘病人的治疗,同时也可以用于脑血管的扩张剂。2-(2-甲基苯基)-2-硝基环己-1-酮在治疗神经性系统疾病具有良好的效果。而2-芳基-1-环己醇作为合成上述化合物的重要中间体,因此针对其开发快速高效的合成方法具有重要意义。2-Aryl-1-cyclohexanol is an important intermediate in the synthesis of many biologically active molecules, drugs, and other materials. For example: 4-cycloalkoxybenzonitrile is an androgen receptor modulator. It can effectively reduce sebum secretion and stimulate hair growth, thus bringing good news to patients with hair loss; ketamine is a type of intravenous general anesthetic, clinically used as a general anesthetic or anesthesia induction agent, and has a bronchodilator effect, so it is also suitable for In the treatment of asthma patients, it can also be used as a dilator of cerebral blood vessels. 2-(2-Methylphenyl)-2-nitrocyclohexan-1-one has good effects in the treatment of neurological diseases. 2-Aryl-1-cyclohexanol is an important intermediate in the synthesis of the above compounds, so it is of great significance to develop a rapid and efficient synthesis method for it.
利用三元环氧化合物氧化环己烯和芳基溴在金属锂试剂(如正、叔丁基锂)的作用下,可以以较理想的收率得到2-芳基-1-环己醇类化合物,是合成该类化合物的一类高效手段。例如,张辅民等以邻氯溴苯和氧化环己烯为原料,采用叔丁基锂作为锂试剂,在低温条件下,可以合成得到2-(2-氯苯基)环己醇,最终合成氯胺酮;薛涛等以2-(2-甲基苯基)环己醇为原料合成了2-(2-甲基苯基)-2-硝基环己-1-酮,该药物具有治疗神经系统的作用;唐世忠等以苯基环己醇为原料,进行氧化,然后利用PTSA催化a-支酮的氟化,可用于氟化季碳中心的构建。By using three-membered epoxy compounds to oxidize cyclohexene and aryl bromide under the action of metallic lithium reagents (such as n- and tert-butyllithium), 2-aryl-1-cyclohexanols can be obtained in a relatively ideal yield. Compounds are an efficient means of synthesizing such compounds. For example, Zhang Fumin et al. used o-chlorobromobenzene and cyclohexene oxide as raw materials, and used tert-butyllithium as the lithium reagent. Under low temperature conditions, 2-(2-chlorophenyl)cyclohexanol could be synthesized, and finally ketamine was synthesized. ; Xue Tao et al. synthesized 2-(2-methylphenyl)-2-nitrocyclohexan-1-one using 2-(2-methylphenyl)cyclohexanol as raw material. This drug has the effect of treating the nervous system. Function; Tang Shizhong et al. used phenylcyclohexanol as raw material, oxidized it, and then used PTSA to catalyze the fluorination of a-branchone, which can be used to construct the fluorinated quaternary carbon center.
然而,上述反应合成2-芳基-1-环己醇虽然收率高,效果也比较好,但是需要用到危险性较高的叔丁基锂/丁基锂;另外,体系中采用的叔丁基锂和三氟化硼乙醚溶液对水和空气敏感,而且反应需要在零下80℃等低温条件下进行,对反应操作的要求很高。同时,由于反应的危险性以及对温度的苛刻要求,导致该反应难于进行放大生产。目前对于2-芳基-1-环己醇的合成,现有技术存在着诸多问题,包括危险系数,能耗较大,操作繁琐等。因此,针对该类化合物开发新的合成技术具有重要的研究意义和应用价值。However, although the above reaction to synthesize 2-aryl-1-cyclohexanol has a high yield and relatively good effect, it requires the use of highly dangerous tert-butyllithium/butyllithium; in addition, the tert-butyllithium/butyllithium used in the system Butyllithium and boron trifluoride ether solutions are sensitive to water and air, and the reaction needs to be carried out at low temperatures such as minus 80°C, which places high requirements on reaction operations. At the same time, due to the danger of the reaction and the strict requirements on temperature, the reaction is difficult to scale up. Currently, there are many problems in the existing technology for the synthesis of 2-aryl-1-cyclohexanol, including risk factors, high energy consumption, and cumbersome operations. Therefore, the development of new synthesis technologies for this type of compounds has important research significance and application value.
发明内容Contents of the invention
为了解决现有技术存在的不足,包括危险系数,能耗较大,操作繁琐等,本发明提出了一种基于连续流反应技术快速制备2-芳基-1-环己醇的方法及其应用。In order to solve the shortcomings of the existing technology, including risk factor, large energy consumption, cumbersome operation, etc., the present invention proposes a method for rapidly preparing 2-aryl-1-cyclohexanol based on continuous flow reaction technology and its application. .
本发明提供了一种基于连续流反应技术快速制备2-芳基-1-环己醇的方法,该工艺依靠氮气平衡系统压力,利用连续流实验泵设备通过连续进料、出料以实现连续化生产,以物料1为反应物,经锂卤交换反应、亲核取代反应、路易斯酸开环反应,制备得到产物2-芳基-1-环己醇。The invention provides a method for rapidly preparing 2-aryl-1-cyclohexanol based on continuous flow reaction technology. The process relies on nitrogen to balance the system pressure and utilizes continuous flow experimental pump equipment to achieve continuous feeding and discharging. Chemical production, using material 1 as the reactant, the product 2-aryl-1-cyclohexanol is prepared through lithium halide exchange reaction, nucleophilic substitution reaction, and Lewis acid ring-opening reaction.
本发明方法是利用溴苯、丁基锂、环氧、三氟化硼乙醚,采用连续流动化学技术,合成2-芳基-1-环己醇目标产物。该反应通过依次加料的方式,历经丁基锂与芳基溴的锂卤交换得到芳基锂中间体,进一步与环氧发生亲核取代,再在三氟化硼的作用下发生开环,最终通过水淬灭反应,得到目标产物2-芳基-1-环己醇。The method of the invention utilizes bromobenzene, butyllithium, epoxy, boron trifluoride ether and continuous flow chemical technology to synthesize the target product of 2-aryl-1-cyclohexanol. By sequentially adding materials, this reaction undergoes lithium halide exchange between butyllithium and aryl bromide to obtain an aryllithium intermediate, which is further nucleophilically substituted with epoxy, and then ring-opened under the action of boron trifluoride. Finally, By quenching the reaction with water, the target product 2-aryl-1-cyclohexanol is obtained.
本发明方法的反应路线为:The reaction route of the method of the present invention is:
其中,R表示取代基团为芳环上除了溴取代基之外,任意位点上甲基、甲氧基、卤素(氟,氯)、烷基、芳香基、杂芳香基、烷氧基、氨基、羟基、三氟甲基等取代基中的任意一种或多种。Among them, R means that the substituent group on the aromatic ring is methyl, methoxy, halogen (fluorine, chlorine), alkyl, aryl, heteroaryl, alkoxy, Any one or more substituents such as amino, hydroxyl, and trifluoromethyl.
所述方法包括:The methods include:
(1)锂卤交换(1) Lithium halide exchange
反应开始前,先将管路充满四氢呋喃,使管路内无空气存在,然后在氮气保护下,将物料1与锂试剂按当量比例泵入连续流反应装置,在第一溶剂中,在-60℃~-80℃温度下,反应5-8分钟进行锂卤交换,生成中间体2;Before starting the reaction, first fill the pipeline with tetrahydrofuran so that there is no air in the pipeline. Then, under nitrogen protection, pump material 1 and lithium reagent into the continuous flow reaction device in equivalent proportions. In the first solvent, at -60 At a temperature of ℃ ~ -80 ℃, react for 5-8 minutes to perform lithium halide exchange to generate intermediate 2;
(2)亲核取代(2) Nucleophilic substitution
将所述步骤(1)生成的活性中间体2,继续通入连续流反应装置,然后将氧化环己烯溶液按比例泵入连续流反应装置,在第二溶剂中,在-60℃~-80℃温度下,反应5-7分钟进行亲核取代,生成活性中间体3;Continue to pass the active intermediate 2 generated in step (1) into the continuous flow reaction device, and then pump the cyclohexene oxide solution into the continuous flow reaction device in proportion, in the second solvent, at -60°C~- At 80°C, react for 5-7 minutes to perform nucleophilic substitution to generate active intermediate 3;
(3)路易斯酸开环(3) Lewis acid ring opening
将所述步骤(2)生成的活性中间体3,继续通入连续流反应装置,然后将三氟化硼乙醚溶液按比例泵入连续流反应装置,在第三溶剂中,在-70℃~-85℃温度下,反应8-10分钟,发生开环反应,得到2-芳基-1-环己醇产物。Continue to pass the active intermediate 3 generated in step (2) into the continuous flow reaction device, and then pump the boron trifluoride ether solution into the continuous flow reaction device in proportion, in the third solvent, at -70°C~ At a temperature of -85°C, react for 8-10 minutes, a ring-opening reaction occurs, and the 2-aryl-1-cyclohexanol product is obtained.
在一些具体实施方案中,操作步骤包括如下:In some embodiments, the steps include:
先将管路充满四氢呋喃,使管路内无空气存在,然后在氮气保护下,将物料1与丁基锂按一定当量比例泵入连续流反应装置,在-80℃下,反应5min~8min进行锂卤交换,所生成的活性中间体2继续通过连续流动装置;然后将氧化环己烯溶液按一定比例泵入连续流反应装置,在-80℃下,反应5min~7min进行亲核取代,生成中间体3;所生成的活性中间体3继续通入连续流反应装置,然后将三氟化硼乙醚溶液按一定比例泵入连续流反应装置,在-80℃下,反应8min~10min,进行路易斯酸开环,得到2-芳基-1-环己醇。First, fill the pipeline with tetrahydrofuran so that there is no air in the pipeline. Then, under nitrogen protection, pump material 1 and butyl lithium into the continuous flow reaction device in a certain equivalent ratio. The reaction is carried out at -80°C for 5 to 8 minutes. Lithium halide exchange, the generated active intermediate 2 continues to pass through the continuous flow device; then the cyclohexene oxide solution is pumped into the continuous flow reaction device according to a certain proportion, and reacts at -80°C for 5 to 7 minutes to perform nucleophilic substitution to generate Intermediate 3; the generated active intermediate 3 continues to flow into the continuous flow reaction device, and then the boron trifluoride ether solution is pumped into the continuous flow reaction device according to a certain proportion, and the reaction is carried out at -80°C for 8 minutes to 10 minutes, and the Lewis reaction is carried out The acid rings open to give 2-aryl-1-cyclohexanol.
步骤(1)中,合成中间体2中的物料1溶液中所用的第一溶剂为甲苯、四氢呋喃和无水乙醚中的至少一种,其浓度为0.8mol/L~1.5mol/L,流速为6.0mL/min~10.0mL/min;In step (1), the first solvent used in the solution of material 1 in the synthesis of intermediate 2 is at least one of toluene, tetrahydrofuran and anhydrous ether, with a concentration of 0.8 mol/L to 1.5 mol/L, and a flow rate of 6.0mL/min~10.0mL/min;
合成中间体2中的物料1与丁基锂的的当量比1:1~1.5,所述上述温度为-60℃~-80℃;The equivalent ratio of material 1 to butyllithium in the synthesis intermediate 2 is 1:1 to 1.5, and the above temperature is -60°C to -80°C;
合成中间体2中锂卤交换的反应时间为5min~8min;The reaction time of lithium halide exchange in the synthesis intermediate 2 is 5min~8min;
有机锂试剂为丁基锂、仲丁基锂、叔丁基锂中的一种,其流速为4mL/min~6mL/min;The organolithium reagent is one of butyllithium, sec-butyllithium and tert-butyllithium, and its flow rate is 4mL/min~6mL/min;
步骤(2)中,合成中间体3中的氧化环己烯溶液中所用的第二溶剂为甲苯、四氢呋喃和无水乙醚中的至少一种,其浓度为0.8mol/L~1.5mol/L,流速为5mL/min~8mL/min;In step (2), the second solvent used in the cyclohexene oxide solution in the synthesis intermediate 3 is at least one of toluene, tetrahydrofuran and anhydrous ether, and its concentration is 0.8mol/L to 1.5mol/L. The flow rate is 5mL/min~8mL/min;
合成中间体3中的物料1与氧化环己烯的当量比为1:0.9~1;所述上述温度为-60℃~-80℃;The equivalent ratio of material 1 in the synthesis intermediate 3 to cyclohexene oxide is 1:0.9~1; the above-mentioned temperature is -60°C~-80°C;
合成中间体3中亲核取代的反应时间为3min~5min;The reaction time of nucleophilic substitution in synthetic intermediate 3 is 3 to 5 minutes;
步骤(3)中,合成目标产物4即产物2-芳基-1-环己醇时所用到的三氟化硼乙醚溶液中所用的第三溶剂为甲苯、四氢呋喃和无水乙醚中的至少一种,其浓度为1.2mol/L~2.0mol/L,流速为6.5mL/min~10.0mL/min;In step (3), the third solvent used in the boron trifluoride diethyl ether solution used to synthesize the target product 4, that is, the product 2-aryl-1-cyclohexanol, is at least one of toluene, tetrahydrofuran and anhydrous diethyl ether. species, its concentration is 1.2mol/L~2.0mol/L, and the flow rate is 6.5mL/min~10.0mL/min;
合成目标产物4时物料1与三氟化硼乙醚的当量比为1:1.5~2,所述上述温度为-70℃~-85℃;When synthesizing target product 4, the equivalent ratio of material 1 to boron trifluoride ether is 1:1.5~2, and the above-mentioned temperature is -70°C~-85°C;
合成目标产物4时路易斯开环反应的反应时间为5min~10min。The reaction time of the Lewis ring-opening reaction when synthesizing the target product 4 is 5 to 10 minutes.
本发明方法中,所述连续流反应装置包括:连续流反应管道,为PTFE特氟龙管或316L不锈钢管;微混混合器;温度控制系统;连续流反应实验泵,连接反应物的进口;连续流反应稳压装置,连接产品的出口;连续流产物收集装置,连接稳压装置的出口。In the method of the present invention, the continuous flow reaction device includes: a continuous flow reaction pipe, which is a PTFE Teflon pipe or a 316L stainless steel pipe; a micro-mixing mixer; a temperature control system; a continuous flow reaction experimental pump connected to the inlet of the reactant; The continuous flow reaction voltage stabilizing device is connected to the outlet of the product; the continuous flow product collection device is connected to the outlet of the voltage stabilizing device.
本发明方法中,所述连续流反应实验泵包括泵1-泵4;其中,In the method of the present invention, the continuous flow reaction experimental pump includes pump 1-pump 4; wherein,
连续流反应实验泵1使物料1的四氢呋喃和甲苯溶液通入到管路中,其中溶液浓度为0.5mol/L~1mol/L,流速为6.0mL/min~10.0mL/min;Continuous flow reaction experiment pump 1 allows the tetrahydrofuran and toluene solution of material 1 to pass into the pipeline, where the solution concentration is 0.5mol/L~1mol/L, and the flow rate is 6.0mL/min~10.0mL/min;
连续流反应实验泵2使锂试剂通入到管路中,其流速为4mL/min~6mL/min;The continuous flow reaction experimental pump 2 allows the lithium reagent to pass into the pipeline, and its flow rate is 4mL/min~6mL/min;
连续流反应实验泵3使氧化环己烯的四氢呋喃溶液通入到管路中,其浓度为0.8mol/L~1.5mol/L,流速为5mL/min~8mL/min;The continuous flow reaction experiment pump 3 passes the tetrahydrofuran solution of cyclohexene oxide into the pipeline, the concentration is 0.8mol/L~1.5mol/L, and the flow rate is 5mL/min~8mL/min;
连续流反应实验泵4使三氟化硼-乙醚的甲苯溶液通入到管路中,其浓度为1.2mol/L~2.0mol/L,流速为6.5~10.0mL/min。The continuous flow reaction experimental pump 4 passes the toluene solution of boron trifluoride-diethyl ether into the pipeline, with a concentration of 1.2 mol/L to 2.0 mol/L and a flow rate of 6.5 to 10.0 mL/min.
所述反应的整体上反应温度为-80℃,整体上反应的保留时间为20min~30min。The overall reaction temperature of the reaction is -80°C, and the overall retention time of the reaction is 20 to 30 minutes.
本发明进一步地包括后处理步骤:The present invention further includes post-processing steps:
步骤4)将产物通过萃取分液得到有机相,然后再用无水硫酸钠将有机相干燥,通过旋转蒸发仪将有机相旋干,得到白色蜡状固体;和/或,Step 4) Separate the product through extraction to obtain an organic phase, then dry the organic phase with anhydrous sodium sulfate, and spin the organic phase to dryness using a rotary evaporator to obtain a white waxy solid; and/or,
步骤5)所收集的产品通过GC监测,纯度为80~90%。Step 5) The collected product is monitored by GC, and the purity is 80-90%.
本发明还提出了如下所示的中间体2,The present invention also proposes intermediate 2 shown below,
其中,R表示取代基团为芳环上除了溴取代基之外,任意位点上甲基、甲氧基、卤素(氟,氯)、烷基、芳香基、杂芳香基、烷氧基、氨基、羟基、三氟甲基等取代基中的任意一种或多种。Among them, R means that the substituent group on the aromatic ring is methyl, methoxy, halogen (fluorine, chlorine), alkyl, aryl, heteroaryl, alkoxy, Any one or more substituents such as amino, hydroxyl, and trifluoromethyl.
本发明还提出了一种中间体3,其结构为:The present invention also proposes an intermediate 3, whose structure is:
其中,R表示取代基团为芳环上除了溴取代基之外,任意位点上甲基、甲氧基、卤素(氟,氯)、烷基、芳香基、杂芳香基、烷氧基、氨基、羟基、三氟甲基等取代基中的任意一种或多种。Among them, R means that the substituent group on the aromatic ring is methyl, methoxy, halogen (fluorine, chlorine), alkyl, aryl, heteroaryl, alkoxy, Any one or more substituents such as amino, hydroxyl, and trifluoromethyl.
本发明创新有益效果包括,将成本低廉的合成路径与连续流技术相结合,解决了釜试反应的放大效应,降低了活性锂试剂的危险操作系数,降低了反应所需的能耗,节约了成本,为合成2-芳基-1-环己醇提供了一种高效,安全,成本低廉的工艺方法,使反应在可控的连续化条件下获得较高纯度的粗产品(GC纯度为80%~90%),高于釜试的纯度(GC纯度为65%~70%)。本发明方法中结合了连续流反应具有的较好的传热传质的效果,连续流反应不存在放大效应,避免了放大效应引起的损失,连续流反应具有操作简单,危险系数低等,包括连续流反应装置具有传热传质好,反应时间短,能耗相对较少等优点。本发明提出的使用连续流方法合成2-芳基-1-环己醇的方法,在合成技术领域具有重要意义和应用价值。The innovative beneficial effects of the present invention include combining a low-cost synthesis path with continuous flow technology, solving the amplification effect of the kettle test reaction, reducing the dangerous operating coefficient of the active lithium reagent, reducing the energy consumption required for the reaction, and saving cost, providing an efficient, safe and low-cost process for the synthesis of 2-aryl-1-cyclohexanol, allowing the reaction to obtain a higher purity crude product (GC purity 80 %~90%), which is higher than the purity of the kettle test (GC purity is 65%~70%). The method of the present invention combines the better heat and mass transfer effect of the continuous flow reaction. The continuous flow reaction has no amplification effect and avoids losses caused by the amplification effect. The continuous flow reaction has the advantages of simple operation and low risk factor, including The continuous flow reaction device has the advantages of good heat and mass transfer, short reaction time, and relatively low energy consumption. The method proposed by the present invention for synthesizing 2-aryl-1-cyclohexanol using a continuous flow method has important significance and application value in the field of synthesis technology.
附图说明Description of the drawings
图1是本发明合成2-芳基-1-环己醇的方法的工艺流程示意图:其中1,2,3,4为所配好的物料;5,6,7,8为连续流实验泵;9,10,11,12为预冷管;13,16,19为微混装置;14,17,20为温度控制装置检测点;15,18,21为反应的反应管;22该系统的稳压装置;23为该系统的接收装置。Figure 1 is a schematic process flow diagram of the method for synthesizing 2-aryl-1-cyclohexanol according to the present invention: 1, 2, 3, and 4 are prepared materials; 5, 6, 7, and 8 are continuous flow experimental pumps. ; 9, 10, 11, 12 are pre-cooling tubes; 13, 16, 19 are micro-mixing devices; 14, 17, 20 are temperature control device detection points; 15, 18, 21 are reaction tubes; 22 the system Voltage stabilizing device; 23 is the receiving device of the system.
图2和图3为工艺流程实物图。Figures 2 and 3 are physical diagrams of the process flow.
具体实施方式Detailed ways
结合以下具体实施例和附图,对发明作进一步的详细说明。实施本发明的过程、条件、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。The invention will be further described in detail with reference to the following specific embodiments and drawings. The process, conditions, experimental methods, etc. for implementing the present invention, except those specifically mentioned below, are common knowledge and common sense in the field, and the present invention has no special limitations.
实施例1Example 1
如图1所示,将溴苯的THF溶液装入三口瓶1中,nBuLi装入三口瓶2中,氧化环己烯的THF溶液装入三口瓶3中,三氟化硼乙醚的甲苯溶液装入三口瓶4中,温度控制装置设置为-60℃,溴苯的THF溶液和nBuLi分别由连续流实验泵5和6打入,使其在反应管15中进行锂卤交换6min;然后将上述所得到的中间体2和氧化环己烯的THF溶液在反应管18中进行亲核取代4min;最后将第二步所得到的中间体3与三氟化硼乙醚的甲苯溶液在反应管21中进行开环,保留时间为7min;然后将反应物通入23(存有1/3的冰水混合物)中进行淬灭,然后将反应液进行分液,盐水洗一次,干燥,旋干通过GC进行分析,得到粗产品的纯度为90.3%;As shown in Figure 1, put the THF solution of bromobenzene into the three-necked flask 1, put nBuLi into the three-necked flask 2, put the THF solution of cyclohexene oxide into the three-necked flask 3, and put the toluene solution of boron trifluoride ether into into the three-necked flask 4, the temperature control device is set to -60°C, and the THF solution and nBuLi of bromobenzene are driven in by the continuous flow experimental pumps 5 and 6 respectively, so that the lithium halide exchange is performed in the reaction tube 15 for 6 minutes; then the above The obtained intermediate 2 and the THF solution of cyclohexene oxide were subjected to nucleophilic substitution in reaction tube 18 for 4 minutes; finally, the intermediate 3 obtained in the second step and the toluene solution of boron trifluoride ether were placed in reaction tube 21 Carry out ring opening with a retention time of 7 minutes; then pass the reactant into 23 (containing 1/3 of the ice-water mixture) for quenching, then separate the reaction solution, wash once with brine, dry, spin dry and pass through GC After analysis, the purity of the crude product was 90.3%;
1HNMR(400MHz,CDCl3)δ7.32(t,J=7.5Hz,2H),7.24(dd,J=7.6,2.6Hz,3H),3.65(td,J=10.0,4.2Hz,1H),2.41(m,1H),2.14-2.05(m,1H),1.85(dd,J=12.2,3.4Hz,2H),1.79-1.70(m,1H),1.59-1.27(m,6H). 1 HNMR (400MHz, CDCl 3 ) δ7.32 (t, J = 7.5 Hz, 2H), 7.24 (dd, J = 7.6, 2.6 Hz, 3H), 3.65 (td, J = 10.0, 4.2 Hz, 1H), 2.41(m,1H),2.14-2.05(m,1H),1.85(dd,J=12.2,3.4Hz,2H),1.79-1.70(m,1H),1.59-1.27(m,6H).
实施例2Example 2
具体合成过程同本发明实施例1,只是将溴苯换为2-甲基溴苯,温度控制装置设置为-65℃;得到产品的纯度为87.2%;The specific synthesis process is the same as in Example 1 of the present invention, except that bromobenzene is replaced by 2-methylbromobenzene, and the temperature control device is set to -65°C; the purity of the obtained product is 87.2%;
1HNMR(400MHz,CDC13)δ7.27-7.23(m,1H),7.22-7.14(m,2H),7.13-7.08(m,1H),3.83-3.71(m,1H),2.83-2.68(m,1H),2.36(s,3H),2.18-2.07(m,1H),1.94-1.70(m,3H),1.69-1.59(m,1H),1.51-1.27(m,4H). 1 HNMR (400MHz, CDC1 3 ) δ7.27-7.23(m,1H),7.22-7.14(m,2H),7.13-7.08(m,1H),3.83-3.71(m,1H),2.83-2.68( m,1H),2.36(s,3H),2.18-2.07(m,1H),1.94-1.70(m,3H),1.69-1.59(m,1H),1.51-1.27(m,4H).
实施例3Example 3
具体合成过程同本发明实施例2,只是将2-甲基溴苯换为3-甲基溴苯;得到产品的纯度为85.9%;The specific synthesis process is the same as Example 2 of the present invention, except that 2-methylbromobenzene is replaced by 3-methylbromobenzene; the purity of the obtained product is 85.9%;
1HNMR(400MHZ,CDC13)δ7.26-7.18(m,1H),7.09-7.01(m,3H),3.70--3.58(m,1H),2.43-2.35(m,1H),2.34(s,3h),2.14-2.06(m,1h),1.88-1.71(m,3H),1.68-1.60(m,1H),1.56-1.28(m,4h). 1 HNMR (400MHZ, CDC1 3 ) δ7.26-7.18(m,1H),7.09-7.01(m,3H),3.70--3.58(m,1H),2.43-2.35(m,1H),2.34(s ,3h),2.14-2.06(m,1h),1.88-1.71(m,3H),1.68-1.60(m,1H),1.56-1.28(m,4h).
实施例4Example 4
具体合成过程同本发明实施例1,只是将溴苯换为2-氟溴苯,得到产品的纯度为88.7%;The specific synthesis process is the same as in Example 1 of the present invention, except that bromobenzene is replaced by 2-fluorobromobenzene, and the purity of the product obtained is 88.7%;
1H NMR(400MHz,CDC13),δ7.28(m,1H),7.20(m,1H),7.12(m,1H),7.04(m,1H),3.79(m,1H),2.83(m,1H),2.17-2.10(m,1H),1.94-1.81(m,2H),1.81-1.69(m,1H),1.66-1.18(m,4H),0.93-0.79(m,1H). 1 H NMR (400MHz, CDC1 3 ), δ7.28(m,1H),7.20(m,1H),7.12(m,1H),7.04(m,1H),3.79(m,1H),2.83(m ,1H),2.17-2.10(m,1H),1.94-1.81(m,2H),1.81-1.69(m,1H),1.66-1.18(m,4H),0.93-0.79(m,1H).
实施例5Example 5
具体合成过程同本发明实施例4,只是将2-氟溴苯换为3-氟溴苯;得到产品的纯度为89.8%;The specific synthesis process is the same as Example 4 of the present invention, except that 2-fluorobromobenzene is replaced by 3-fluorobromobenzene; the purity of the obtained product is 89.8%;
1H NMR(400MHz,CDC13)δ87.32-7.27(m,1H),7.03(d,J=7.5Hz,1H),6.94(dd J=16.8,9.1Hz,2H)、3.64(td,J=9.9,4.2Hz,1H),2.49-2.38(m,1H),2.12(d,J=8.0Hz,1H),1.86(d,J=10.2Hz,2H) 1 H NMR (400MHz, CDC1 3 ) δ 87.32-7.27 (m, 1H), 7.03 (d, J = 7.5Hz, 1H), 6.94 (dd J = 16.8, 9.1Hz, 2H), 3.64 (td, J =9.9,4.2Hz,1H),2.49-2.38(m,1H),2.12(d,J=8.0Hz,1H), 1.86(d,J=10.2Hz,2H)
实施例6Example 6
具体合成过程同本发明实施例1,只是将溴苯换为2-氯溴苯温度控制装置设置为-78℃;得到产品的纯度为82.3%。The specific synthesis process is the same as Example 1 of the present invention, except that bromobenzene is replaced with 2-chlorobromobenzene and the temperature control device is set to -78°C; the purity of the obtained product is 82.3%.
1H NMR(400MHz,CDCl3)δ7.39(d,J=8.0Hz,1H),7.33(d,J=7.8Hz,1H),7.26(q,J=8.0,7.5Hz,2H),7.21–7.10(m,2H),3.90–3.78(m,1H),3.12(m,1H),2.36(m,1H),2.16(m,1H),1.97–1.65(m,4H),1.55–1.18(m,4H). 1 H NMR (400MHz, CDCl 3 ) δ7.39 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.26 (q, J = 8.0, 7.5 Hz, 2H), 7.21 –7.10(m,2H),3.90–3.78(m,1H),3.12(m,1H),2.36(m,1H),2.16(m,1H),1.97–1.65(m,4H),1.55–1.18 (m,4H).
实施例7Example 7
具体合成过程同本发明实施例1,只是将溴苯换为4-苯基溴苯,温度控制装置设置为-82℃;得到产品的纯度为83.7%The specific synthesis process is the same as Example 1 of the present invention, except that bromobenzene is replaced with 4-phenylbromobenzene, and the temperature control device is set to -82°C; the purity of the obtained product is 83.7%
1H NMR(400MHz,CDCl3):δ7.61-7.68(m,4H),7.48-7.05(m,2H),7.37-7.44(m,3H),3.70-3.78(m,1H),2.50-2.58(m,1H),2.17-2.21(m,1H),1.93-1.98(m,2H),1.85(s,2H),1.38-1.67(m,4H). 1 H NMR (400MHz, CDCl 3 ): δ7.61-7.68(m,4H),7.48-7.05(m,2H),7.37-7.44(m,3H),3.70-3.78(m,1H),2.50- 2.58(m,1H),2.17-2.21(m,1H),1.93-1.98(m,2H),1.85(s,2H),1.38-1.67(m,4H).
本发明的保护内容不局限于以上实施例。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点,本领域技术人员对本发明的简单技术修改或同等替换,都已经被包括在本发明中,并且以所附的权利要求书为保护范围。The protection content of the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art, simple technical modifications or equivalent substitutions of the present invention by those skilled in the art, have been included in the present invention, and are included in the appended The claims represent the scope of protection.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210438652.8A CN114805019B (en) | 2022-04-25 | 2022-04-25 | Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210438652.8A CN114805019B (en) | 2022-04-25 | 2022-04-25 | Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114805019A CN114805019A (en) | 2022-07-29 |
CN114805019B true CN114805019B (en) | 2024-03-12 |
Family
ID=82506792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210438652.8A Active CN114805019B (en) | 2022-04-25 | 2022-04-25 | Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114805019B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116212764B (en) * | 2023-02-20 | 2024-06-21 | 上海荟银化学技术有限公司 | Method for industrially synthesizing 2, 2-diphenyl ethanol by using continuous flow equipment |
CN116283506A (en) * | 2023-02-20 | 2023-06-23 | 上海荟银化学技术有限公司 | A method for preparing 3,4,5-trifluorophenol based on continuous flow reaction technology |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024663A1 (en) * | 2002-08-31 | 2004-03-25 | Clariant Gmbh | Method for the organometallic production of organic intermediate products by halogen-metal exchange reactions |
JP2006241065A (en) * | 2005-03-03 | 2006-09-14 | Fujifilm Finechemicals Co Ltd | Method for producing organic compound using halogen-lithium exchange reaction |
CN105073114A (en) * | 2013-03-14 | 2015-11-18 | 第一三共株式会社 | Medications for Respiratory Diseases |
CN106478367A (en) * | 2016-09-30 | 2017-03-08 | 兰州大学 | A kind of synthesis midbody compound of ketamine and the synthetic method of ketamine |
CN110343050A (en) * | 2018-04-04 | 2019-10-18 | 上海键合医药科技有限公司 | Aromatic compounds and its preparation method and application |
CN110835292A (en) * | 2019-10-12 | 2020-02-25 | 北京海美桐医药科技有限公司 | Method for preparing 2-fluoro-6-trifluoromethylbenzaldehyde by adopting continuous flow reaction device |
ES2837446A1 (en) * | 2019-12-31 | 2021-06-30 | Laboratorios Vinas S A | MANUFACTURING PROCEDURES FOR BROMOMETHYL CYCLOPROPYLKETONE, CYCLOPROPYLCARBONYLMETHYLTRIPHENYLPHOSPHONIUM BROMIDE, CYCLOPROPYLCARBONYL METHYLENETHRIPHENYLPHOSPHORANE, VITAMIN D DERIVATIVES AND CALCIPOTRIOL (Machine-translation by Google Translate, not legally binding) |
CN113264819A (en) * | 2021-05-25 | 2021-08-17 | 都创(上海)医药开发有限公司 | Method for rapidly synthesizing 3-bromo-2-fluorobenzaldehyde based on continuous flow reaction technology |
CN113549042A (en) * | 2021-07-23 | 2021-10-26 | 安庆奇创药业有限公司 | Preparation method of dapagliflozin |
-
2022
- 2022-04-25 CN CN202210438652.8A patent/CN114805019B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024663A1 (en) * | 2002-08-31 | 2004-03-25 | Clariant Gmbh | Method for the organometallic production of organic intermediate products by halogen-metal exchange reactions |
JP2006241065A (en) * | 2005-03-03 | 2006-09-14 | Fujifilm Finechemicals Co Ltd | Method for producing organic compound using halogen-lithium exchange reaction |
CN105073114A (en) * | 2013-03-14 | 2015-11-18 | 第一三共株式会社 | Medications for Respiratory Diseases |
CN106478367A (en) * | 2016-09-30 | 2017-03-08 | 兰州大学 | A kind of synthesis midbody compound of ketamine and the synthetic method of ketamine |
CN110343050A (en) * | 2018-04-04 | 2019-10-18 | 上海键合医药科技有限公司 | Aromatic compounds and its preparation method and application |
CN110835292A (en) * | 2019-10-12 | 2020-02-25 | 北京海美桐医药科技有限公司 | Method for preparing 2-fluoro-6-trifluoromethylbenzaldehyde by adopting continuous flow reaction device |
ES2837446A1 (en) * | 2019-12-31 | 2021-06-30 | Laboratorios Vinas S A | MANUFACTURING PROCEDURES FOR BROMOMETHYL CYCLOPROPYLKETONE, CYCLOPROPYLCARBONYLMETHYLTRIPHENYLPHOSPHONIUM BROMIDE, CYCLOPROPYLCARBONYL METHYLENETHRIPHENYLPHOSPHORANE, VITAMIN D DERIVATIVES AND CALCIPOTRIOL (Machine-translation by Google Translate, not legally binding) |
CN113264819A (en) * | 2021-05-25 | 2021-08-17 | 都创(上海)医药开发有限公司 | Method for rapidly synthesizing 3-bromo-2-fluorobenzaldehyde based on continuous flow reaction technology |
CN113549042A (en) * | 2021-07-23 | 2021-10-26 | 安庆奇创药业有限公司 | Preparation method of dapagliflozin |
Non-Patent Citations (4)
Title |
---|
Diversity-Oriented Synthesis of Bioactive Azaspirocycles;Lance T. Lepovitz et al.;《Tetrahedron》;第1-10页 * |
Promoting Reductive Tandem Reactions of Nitrostyrenes with Mo(CO)6 and a Palladium Catalyst To Produce 3H‑Indoles;Navendu Jana et al.;《J. Am. Chem. Soc》;第137卷;第6738-6741页、Supporting InformationS5页 * |
Synthesis of methoxetamine, its metabolites and deuterium labelled analog as analytical standards and their HPLC and chiral capillary electrophoresis separation;B. Jurasek et al.;《RSC Adv》;第7卷;第56691-56696页 * |
铜盐催化氧化环己烯的开环加成反应;鄢明;化学通报;20040618(06);452-460 * |
Also Published As
Publication number | Publication date |
---|---|
CN114805019A (en) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114805019B (en) | Method for synthesizing 2-aryl-1-cyclohexanol based on continuous flow reaction technology | |
CN102924301B (en) | Preparation method of N,N-bis(2-hydroxyethyl)isopropanolamine | |
CN109721585B (en) | Preparation method of baroxavir key intermediate | |
CN111635300B (en) | Method for preparing deuterated benzoin by taking heavy water as deuterium source | |
CN105061373A (en) | Synthesis method of dapagliflozin isomer impurity | |
CN105061230B (en) | Method for preparing dapoxetine hydrochloride | |
CN110642748B (en) | O- (2-trifluoromethyl-2-hydroxyethyl) oxime ether derivative and synthetic method and application thereof | |
CN114394993B (en) | Preparation method of dapagliflozin intermediate | |
CN101747212A (en) | Method for synthesizing 3-amino-1-adamantanol | |
CN116730812A (en) | Preparation method of 4,4' -difluorobenzophenone | |
CN102491888B (en) | Acyl-substituted triptycene and preparation method thereof | |
CN116655503A (en) | Preparation method of 1-aryl-3-arylsulfinyl bicyclo [1.1.1] pentane | |
CN110590621B (en) | Method for synthesizing 1, 2-bis (arylsulfonyl) ethylene derivative by copper-catalyzed terminal alkyne | |
CN104628555B (en) | A kind of synthetic method of pharmaceutical intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid | |
CN110015960A (en) | Preparation method and application of 1,3-bis(4,4-methylcarboxylate phenyl)acetone | |
CN110372718B (en) | Difluoromethane thiochromanonthiophene compound and preparation method thereof | |
CN113511954B (en) | Continuous flow preparation method of 1,2, 3-trichloropropane | |
CN103641692A (en) | Preparation of novel fluorine-containing bisphenol compound | |
CN108822060B (en) | A kind of 3-aryl substituted oxetane and preparation method thereof | |
CN116444459B (en) | A method for preparing functionalized allylamine compounds | |
CN118638137A (en) | A method for synthesizing polyfluorophenylboronic acid based on continuous flow reaction technology | |
CN108069835A (en) | A kind of chiral helicene with dinaphthol structure and preparation method thereof | |
CN109336748B (en) | Preparation method of NASH-resistant drug intermediate diformaldehyde magnolol | |
CN113402361B (en) | Gem difluoro vinyl transfer reagent and preparation method thereof | |
CN116283506A (en) | A method for preparing 3,4,5-trifluorophenol based on continuous flow reaction technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |